Pune, India | November 11, 2025
In a breakthrough, Dupixent (dupilumab) achieved all primary and secondary endpoints in a pivotal phaseâ¯3 trial. The trial targeted moderate-to-severe atopic dermatitis in children as young as six months. Adding Dupixent to standard topical corticosteroid care improved skin clearance, reduced itching, and enhanced quality of life.
The randomized, double-blind, placebo-controlled trial enrolled 162 children aged sixâ¯months to fiveâ¯years who had uncontrolled moderate-to-severe atopic dermatitis despite topical therapy. After 16â¯weeks, 28â¯% of participants receiving Dupixent plus topical corticosteroids achieved “clear or almost-clear” skin. The control group achieved only 4â¯%. Moreover, 53â¯% of children in the Dupixent arm reached a ≥75 % improvement in the Eczema Area and Severity Index. The control group reached 11â¯%.
Beyond skin clearance, Dupixent reduced overall disease severity by an average of 70â¯%, compared to a 20â¯% reduction with placebo. It improved itching by 49â¯%, while the placebo improved only 2â¯%. Patients also reported better sleep and less skin pain. Caregivers noticed significant improvements in quality of life. The Dupixent arm experienced 50â¯% fewer skin infections and nearly 70â¯% fewer total infection events than the placebo group.
“This condition severely affects infants, young children, and their caregivers,” said the study’s lead investigator. “Over half of the children had dermatitis covering more than half their bodies. Nearly a third previously used systemic immunosuppressants. Dupixent dramatically reduced the disease’s impact on these children and families.”
Dupixent targets the IL-4 and IL-13 pathways, which drive type-2 inflammation. It does not broadly suppress the immune system. In the trial, 64â¯% of Dupixent-treated children experienced adverse events, compared to 74â¯% of placebo-treated children. Common events included nasopharyngitis, upper respiratory tract infection, conjunctivitis, herpes viral infections, and injection-site reactions.
This trial is part of a larger clinical program, enrolling about 3,500 children, adolescents, and adults with atopic dermatitis. It is the largest Phaseâ¯3 trial program in this indication. The results expand Dupixent’s approved indications to very young pediatric populations. The drug is already approved for children aged sixâ¯years and older with uncontrolled moderate-to-severe atopic dermatitis.
Regulatory submissions are expected based on these results. Approval could expand the indication to children under six years. “When infants develop moderate-to-severe atopic dermatitis, it can affect their early childhood significantly,” said the research program director. “Standard care includes topical steroids and sometimes immunosuppressive medicines, which may damage delicate skin if used long-term. Dupixent effectively addresses signs and symptoms without broadly suppressing immunity.”
Regulatory agencies will still review safety, manufacturing, and long-term data for the youngest patients. Drug development always carries potential risks, including supply chain or reimbursement challenges.
In summary, these results mark a milestone in pediatric dermatology. Dupixent works quickly: itching improves in one week, and skin clearance appears by two weeks. With strong safety and efficacy data, it may soon provide a new option for infants and young children with moderate-to-severe atopic dermatitis. How these findings translate into real-world use and regulatory approval will determine the treatment’s future, but the outlook for affected families looks promising.
